<?xml version="1.0" encoding="UTF-8"?>
<p id="p0170">Diagnosis approaches that identify antigens for respiratory syncytial virus infection or influenza virus infection directly from clinical samples through immunoassays have been commercialized for decades; they are capable of showing results in a few minutes and have low complexity [
 <xref rid="bib81" ref-type="bibr">81</xref>]. Current methods for identification of influenza and respiratory syncytial viruses suffer from suboptimal sensitivity to rule out disease [
 <xref rid="bib82" ref-type="bibr">82</xref>,
 <xref rid="bib83" ref-type="bibr">83</xref>], and SARS-CoV-2 may have the same problem. Experiments with specific guidance for proper interpretation need to be introduced. Test prototypes for other new coronaviruses have not yet obtained permission and regulatory approval is still in progress [
 <xref rid="bib84" ref-type="bibr">84</xref>,
 <xref rid="bib85" ref-type="bibr">85</xref>] (
 <ext-link ext-link-type="uri" xlink:href="http://www.finddx.org/covid-19/pipeline" id="intref0045" xmlns:xlink="http://www.w3.org/1999/xlink">www.finddx.org/covid-19/pipeline</ext-link> on 23 March 2020). Monoclonal antibodies against the SARS-CoV-2 nucleocapsid protein have been developed and may form the basis of future rapid antigen detection tests [
 <xref rid="bib86" ref-type="bibr">86</xref>].
</p>
